New Zealand Oral Anti-Diabetic Drug Market Size and Share - Growth Analysis Report and Forecast Trends (2026-2035)

Market Overview

The New Zealand oral anti-diabetic drug market is shifting from low-cost generics towards value-led, criteria-driven brands. Metformin remains the first-line base, yet empagliflozin products and their combinations now carry most of the revenue, and a single decision-maker, Pharmac, sets who can access which tablet.

Three forces are shaping the market: a growing patient pool, with more than 330,000 people living with type 2 diabetes; broader funded access, as Pharmac removed ethnicity and cardiovascular-risk criteria from 1 September 2026; and system pressure, as diabetes costs Health New Zealand over NZ$2 billion a year.

In May 2026 Pharmac received nearly 1,900 submissions on its proposal, and on 5 August 2026 it announced that about 14,000 more people would gain access in the first year, rising to about 31,000 after five years. From early 2026 prescriptions can also run for 12 months.

Key Market Trends and Insights

• Large and growing patient pool: More than 330,000 New Zealanders were living with type 2 diabetes in August 2026, and a peer-reviewed projection published in January 2025 points to about 502,000 people with diabetes by 2044.
• Wider funded access: Pharmac estimates about 14,000 more people will use empagliflozin-based and injectable products in the first year, rising to about 31,000 after five years, on top of about 145,000 current users.
• Community pharmacy reach: The community pharmacy services agreement covers over 1,000 pharmacies, and Health New Zealand confirmed in November 2025 that prescriptions can run for up to 12 months from early 2026.
• Strong public engagement: Pharmac received nearly 1,900 submissions in May 2026 and changed its proposal after feedback, keeping blood glucose control as the single access test for funded products.

New Zealand Oral Anti-Diabetic Drug Market Size and Forecast

The market is moving from low-cost generic tablets towards higher-value classes that are released through clear access criteria. SGLT2 inhibitors lead in value because empagliflozin and its metformin combination are the main funded brand products, while metformin keeps the widest patient reach. Community pharmacies handle most dispensing, with online and mail-order channels gaining share as long prescriptions spread. Special Authority products carry most revenue, and private-pay oral products grow quickest from a small base. Auckland remains the largest region on population and disease burden, and Waikato grows quickest. Criteria that rest on blood glucose control rather than ethnicity or risk scores, longer prescriptions and tighter supply planning point to a durable change in access rather than a short-lived uplift.

Key Takeaways: New Zealand Oral Anti-Diabetic Drug Market

Funded Access Widening Underpins Volume

Revenue is on course to expand by about 57% across the decade, from USD 50.70 million in 2025 to USD 79.49 million in 2035 at a 4.6% CAGR. Pharmac's decision of 5 August 2026 adds about 14,000 users in the first year and about 31,000 after five years, while pharmacy dispensing remains the main route to patients.

SGLT2 and Unfunded Products Lead Growth

SGLT2 Inhibitors lead in value and grow at an estimated 6.2% CAGR through 2035, while Private Pay and Unfunded products grow at an estimated 7.4% from a small base. Boehringer Ingelheim holds the funded empagliflozin brands, and wider criteria from 1 September 2026 move more patients onto them.

Criteria Reset Reshapes Prescribing

Pharmac removed the ethnicity, cardiovascular-risk and kidney-disease routes and now funds on blood glucose control alone, so prescribers face one simple test. Access to injectable products follows a trial of oral therapy where clinically appropriate.

• Funding applies when HbA1c stays above 53 mmol/mol despite other funded medicines
• Empagliflozin or empagliflozin with metformin is started before liraglutide or dulaglutide
• Changes take effect from 1 September 2026 for four medicines

New Zealand Oral Anti-Diabetic Drug Market Report Summary

Key Insight

Demand rests on a growing diabetes population and broader funded access to newer tablets, while generics keep the widest reach. Auckland leads, and Waikato grows fastest.

Key Trends in the New Zealand Oral Anti-Diabetic Drug Market

The New Zealand oral anti-diabetic drug market is being reshaped by wider funded access, a larger patient pool, tender activity and longer prescriptions.

August 2026 - Pharmac Widens Access to Four Type 2 Diabetes Medicines

• Pharmac announced on 5 August 2026 that access to empagliflozin, empagliflozin with metformin, liraglutide and dulaglutide widens from 1 September 2026.
• About 14,000 more people should benefit in the first year, rising to about 31,000 after five years, on top of about 145,000 current users.
• A single glucose-based test replaces ethnicity and risk criteria, which lifts addressable volume for the funded empagliflozin brands.

May 2026 - Pharmac Consults on Changing Diabetes Medicine Criteria

• Pharmac issued its consultation letter on 14 May 2026, proposing to remove ethnicity criteria and lower the cardiovascular risk threshold.
• It estimated about 10,000 more people would benefit in the first year, rising to about 23,000 after five years.
• Nearly 1,900 submissions led Pharmac to extend consultation by two weeks and revise the final design.

November 2025 - Pharmac Opens Annual Invitation to Tender

• Pharmac released its annual invitation to tender on 3 November 2025, with bids due by 4 pm on 15 December 2025.
• The tender covers supply of pharmaceuticals to hospitals and community pharmacies, and bids go through an electronic portal.
• Tender cycles keep price pressure on older generic classes, which supports the shift of value towards newer branded tablets.

January 2025 - Journal Projection Puts Diabetes Cases Near 500,000 by 2044

• A New Zealand Medical Journal paper published on 24 January 2025 projected about 502,000 people with diabetes by 2044.
• Asian, Pacific and Maori populations are expected to account for most of the rise, with the Asian group growing fastest in proportion.
• A larger and more diverse patient base lifts long-term demand for oral therapy across all regions.

Key Insight

Wider funded access, longer prescriptions and a rising diabetes burden are the main structural forces, while tender-driven price pressure on older generics remains the main risk to value.

Recent Market Developments in the New Zealand Oral Anti-Diabetic Drug Market

Recent developments, presented from the most recent, show expert reaction to the access decision, tender results, community pharmacy performance and new medicines logistics capacity.

August 2026 - Researchers Welcome the Decision and Flag Remaining Gaps

• On 5 August 2026 University of Otago associate professor Andrew Reynolds welcomed the decision and said it reportedly came at minimal extra cost through a new supply deal.
• University of Waikato associate professor Ryan Paul noted that funding still depends on blood glucose staying above target, short of current evidence-based practice.
• Diabetes costs Health New Zealand over NZ$2 billion a year, which keeps cost containment central to future decisions.

July 2026 - Pharmac Publishes Annual Tender Results

• Pharmac published its annual tender results on 29 July 2026.
• The results list no award for metformin, sulfonylureas, gliptins or SGLT2 inhibitors, so existing supply arrangements for oral diabetes tablets continue.
• Stable supply terms give suppliers planning certainty while the access change takes effect on 1 September 2026.

November 2025 - Green Cross Health Reports Half-Year Pharmacy Revenue of NZ$181.7 Million

• Green Cross Health reported on 27 November 2025 that pharmacy revenue was flat at NZ$181.7 million and operating profit fell 14%.
• It cited a shift towards lower-margin dispensary sales and was on track for 200 Care and Advice Health Hubs by the end of 2025.
• Dispensary-led growth confirms that chronic tablets such as diabetes medicines anchor pharmacy volume.

October 2025 - DHL Supply Chain Opens Te Kapua Healthcare Facility in Auckland

• DHL Supply Chain scheduled the opening of its Te Kapua Life Sciences and Healthcare Facility at Mangere, Auckland, for 31 October 2025.
• The site holds licences to sell medicines by wholesale and to pack medicines, serving wholesalers and pharmacies.
• Added licensed pharmaceutical storage in Auckland supports reliable delivery of funded medicines to the largest regional market.

Key Insight

Expert reaction, stable tender outcomes and pharmacy and logistics investment show a system preparing for a larger funded patient base through the forecast period.

New Zealand Oral Anti-Diabetic Drug Industry Segmentation

The Expert Market Research’s report on the New Zealand Oral Anti-Diabetic Drug Market offers a detailed analysis of the market based on the following segments.

Market Breakup by Drug Class

• Metformin and Other Biguanides
• Sulfonylureas
• DPP-4 Inhibitors
• SGLT2 Inhibitors
• Others

SGLT2 Inhibitors lead on value, in our estimate, because empagliflozin and empagliflozin with metformin are the main funded brand products, and they grow fastest at an estimated 6.2% CAGR through 2035 as criteria widen from 1 September 2026. Metformin and Other Biguanides keep the broadest patient reach at low unit prices, with steady growth. Sulfonylureas decline in share as prescribers prefer weight-neutral options. DPP-4 Inhibitors hold a niche, led by vildagliptin, and Others include pioglitazone, acarbose and newer oral incretin products. Pharmac's 5 August 2026 decision covers about 145,000 current users and 14,000 new ones in the first year.

Market Breakup by Distribution Channel

• Community Pharmacies
• Hospital Pharmacies
• Online and Mail-Order Pharmacies
• Others

Community Pharmacies lead, in our estimate, because the pharmacy services agreement covers over 1,000 pharmacies, and Green Cross Health reported pharmacy revenue of NZ$181.7 million in its half-year to September 2025. Hospital Pharmacies supply discharge prescriptions and inpatient therapy and grow in line with admissions. Online and Mail-Order Pharmacies grow fastest at an estimated 5.8% CAGR through 2035, helped by prescriptions of up to 12 months from early 2026. Others include primary care dispensing and rural supply points, which grow modestly.

Market Breakup by Funding Status

• Fully Subsidised
• Special Authority Subsidised
• Private Pay and Unfunded
• Others

Special Authority Subsidised products lead on value, in our estimate, because empagliflozin, empagliflozin with metformin and vildagliptin products are released against clinical criteria, and the single glucose-based test from 1 September 2026 raises eligible volume. Fully Subsidised products, mainly metformin and sulfonylureas, carry the widest unit volume at the lowest price and grow slowly. Private Pay and Unfunded products grow fastest at an estimated 7.4% CAGR through 2035 from a small base, as patients and clinicians seek newer oral options outside the Pharmaceutical Schedule.

Market Breakup by Region

• Auckland
• Wellington
• Canterbury
• Waikato
• Others

Auckland dominates, in our estimate, on the largest population and a high share of Asian, Pacific and Maori residents, and it grows at an estimated 4.4% CAGR through 2035 from a large base; DHL Supply Chain's Te Kapua facility at Mangere, scheduled to open in October 2025, supports distribution. Wellington grows at 4.3%, as the seat of Pharmac and Health New Zealand. Canterbury grows at 4.5% on an ageing population. Waikato is fastest at an estimated 5.2%, where a University of Waikato researcher co-leads the national diabetes network. Others grow at 4.7%.

Competitive Landscape in the New Zealand Oral Anti-Diabetic Drug Market

Competition combines research-based brand owners holding Special Authority products, generic suppliers of older classes, and pharmacy and logistics partners. Entry barriers include Pharmac listing and tender success, Medsafe approval, supply reliability and relationships with pharmacy networks and prescribers.

Boehringer Ingelheim

Boehringer Ingelheim, headquartered in Ingelheim am Rhein, Germany, supplies Jardiance (empagliflozin) and Jardiamet (empagliflozin with metformin) in New Zealand, the main funded SGLT2 brands. Pharmac's 5 August 2026 decision widens access to both from 1 September 2026, with about 14,000 more people expected in the first year. Pharmac released budget impact modelling for the products during its May 2026 consultation.

Novartis

Novartis, headquartered in Basel, Switzerland, supplies Galvus (vildagliptin) and Galvumet (vildagliptin with metformin), the funded DPP-4 inhibitor brands in New Zealand. Pharmac's August 2026 criteria refer to vildagliptin alongside metformin and empagliflozin as a prior step before injectable products, which keeps the gliptin relevant in treatment pathways. The brand serves patients who need an alternative to SGLT2 inhibitors.

Eli Lilly

Eli Lilly, headquartered in Indianapolis, United States, operates in New Zealand through Eli Lilly and Company (NZ) Limited in Newmarket, Auckland. Its Trulicity (dulaglutide) is one of the four medicines covered by Pharmac's 5 August 2026 decision, and prescribers must start empagliflozin products first where clinically appropriate. Lilly therefore shapes oral therapy demand as a pathway partner, even though its funded product is injectable.

Green Cross Health

Green Cross Health, based in Auckland and listed on the NZX, owns the Unichem and Life Pharmacy networks, with 328 pharmacy stores including licensees at the end of March 2025. It reported pharmacy revenue of NZ$181.7 million for the half-year to September 2025 and called for wider pharmacist scope. Chronic tablet dispensing, including diabetes medicines, anchors its volume as prescriptions lengthen.

Other players operating in the New Zealand oral anti-diabetic drug market include Novo Nordisk, AstraZeneca, Merck Sharp and Dohme, Healthcare Logistics, and DHL Supply Chain, alongside generic suppliers, wholesalers, independent pharmacies and online pharmacy operators supplying oral diabetes tablets across New Zealand.

Key Insight

Competition rests on Pharmac listing, Medsafe approval, supply reliability and pharmacy relationships rather than price alone, while access changes could reshape positions among brand owners.